Acute lymphoblastic leukemia in adolescents and young adults.

about

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.

P2860

Q49978793-3FAE73A2-4235-4776-8342-A542A793F1FC

P2860

Acute lymphoblastic leukemia in adolescents and young adults.

Item

http://www.wikidata.org/entity/Q39192991

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Acute lymphoblastic leukemia in adolescents and young adults.

@en

Acute lymphoblastic leukemia in adolescents and young adults.

@nl

type

Item

label

Acute lymphoblastic leukemia in adolescents and young adults.

@en

Acute lymphoblastic leukemia in adolescents and young adults.

@nl

prefLabel

Acute lymphoblastic leukemia in adolescents and young adults.

@en

Acute lymphoblastic leukemia in adolescents and young adults.

@nl

P1476

Acute lymphoblastic leukemia in adolescents and young adults.

@en

P2093

Elias J Jabbour

http://www.w3.org/2001/XMLSchema#string

Michael E Rytting

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study

Use of appropriate initial treatment among adolescents and young adults with cancer.

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

P304

2398-2403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30624

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

P577

2017-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28328172

http://www.w3.org/2001/XMLSchema#string

Acute lymphoblastic leukemia in adolescents and young adults.

about

P2860

P2860

Acute lymphoblastic leukemia in adolescents and young adults.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698